NALIRIFOX for metastatic pancreatic adenocarcinoma: hope or hype?

IF 81.1 1区医学 Q1 ONCOLOGY

Nature Reviews Clinical Oncology Pub Date : 2024-04-25 DOI:10.1038/s41571-024-00896-w

Christopher Nevala-Plagemann, Ignacio Garrido-Laguna

引用次数: 0

Abstract

The FDA has approved nanoliposomal irinotecan, 5-fluorouracil, leucovorin and oxaliplatin (NALIRIFOX) for patients with metastatic pancreatic adenocarcinoma on the basis of results from the NAPOLI 3 trial, in which this four-drug regimen improved overall survival relative to a doublet regimen. Here we discuss how, in the context of prior results from the PRODIGE 4 trial testing 5-fluorouracil, leucovorin, irinotecan and oxaliplatin (modified FOLFIRINOX), NALIRIFOX does not seem to raise the bar, but rather exposes patients and health-care systems to financial toxicities.

查看原文本刊更多论文

NALIRIFOX 治疗转移性胰腺腺癌：希望还是炒作？

在 NAPOLI 3 试验结果的基础上，FDA 批准了纳米脂质体伊立替康、5-氟尿嘧啶、亮霉素和奥沙利铂（NALIRIFOX）用于转移性胰腺腺癌患者的治疗，在该试验中，四药治疗方案相对于双药治疗方案提高了总生存率。在这里，我们将讨论在 PRODIGE 4 试验（测试 5-氟尿嘧啶、亮菌素、伊立替康和奥沙利铂（改良 FOLFIRINOX））结果的背景下，NALIRIFOX 似乎并没有提高标准，反而使患者和医疗系统面临经济上的毒性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Nature Reviews Clinical Oncology 医学-肿瘤学

CiteScore

99.40

自引率

0.40%

发文量

114

审稿时长

6-12 weeks

期刊介绍： Nature Reviews publishes clinical content authored by internationally renowned clinical academics and researchers, catering to readers in the medical sciences at postgraduate levels and beyond. Although targeted at practicing doctors, researchers, and academics within specific specialties, the aim is to ensure accessibility for readers across various medical disciplines. The journal features in-depth Reviews offering authoritative and current information, contextualizing topics within the history and development of a field. Perspectives, News & Views articles, and the Research Highlights section provide topical discussions, opinions, and filtered primary research from diverse medical journals.